Abrocitinib

67 interactions 47 explained in plain English 118 cited references

Also sold as: Cibinqo Cibinqo®

About Abrocitinib

Abrocitinib is used to treat moderate to severe eczema (atopic dermatitis; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in adults and children 12 years of age and older who cannot use other medications for their condition or whose eczema has not responded to other… Read the full Abrocitinib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Cangrelor Abciximab Anagrelide Clopidogrel Aspirin Cilostazol

19 Contraindicated 46 Major 2 Moderate

All (67) Contraindicated (19) Major (46) Moderate (2)

Major

Abrocitinib Lonafarnib Zokinvy Explained Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse effects Details Abrocitinib Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Abrocitinib Mavacamten Camzyos Explained Increased mavacamten exposure, an increased risk of mavacamten-related adverse reactions, reduced abrocitinib exposure and reduced... Details Abrocitinib Mavorixafor Xolremdi Explained Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Details Abrocitinib Morphine Explained Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Abrocitinib Morphine Sulfate Liposome Explained Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Abrocitinib Phenobarbital Fidoquel Explained Reduced abrocitinib exposure and reduced efficacy of abrocitinib Details Abrocitinib Pimozide Explained Increased pimozide exposure and an increased risk of pimozide-related adverse reactions Details Abrocitinib Posaconazole Noxafil Explained Increased posaconazole exposure Details Abrocitinib Primidone Mysoline Explained Reduced abrocitinib exposure and reduced efficacy of abrocitinib Details Abrocitinib Ranolazine Aspruzyo Explained Increased ranolazine exposure and an increased risk of ranolazine-related adverse effects Details Abrocitinib Repotrectinib Augtyro Explained Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Abrocitinib Rifampin Rifadin Explained Decreased abrocitinib and active metabolite exposure Details Abrocitinib Sirolimus Felycin Explained Increased exposure of P-glycoprotein substrate Details Abrocitinib Tacrolimus Astagraf Explained Increased exposure of P-glycoprotein substrate Details Abrocitinib Tegafur Explained Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Abrocitinib Tolvaptan Jynarque Explained Increased exposure of P-glycoprotein substrate Details Abrocitinib Venetoclax Venclexta Explained Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Abrocitinib Voriconazole Vfend Explained Increased abrocitinib exposure, an increased risk of abrocitinib-related adverse effects, an increased voriconazole exposure and a... Details Abrocitinib Cyclosporine Injection Atopica Increased exposure of P-glycoprotein substrate Details Abrocitinib Cyclosporine Ophthalmic Cequa Increased exposure of P-glycoprotein substrate Details Abrocitinib Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Abrocitinib Fluorouracil Injection Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Abrocitinib Fluorouracil Topical Carac Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Abrocitinib Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details

Moderate

Abrocitinib Sparsentan Filspari Explained Reduced CYP2C19/CYP2C9 substrate exposure and reduced efficacy of CYP2C19/CYP2C9 substrate Details Abrocitinib Tenofovir Alafenamide Explained Increased tenofovir alafenamide exposure and an increased risk of tenofovir alafenamide-related adverse effects Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.